How Does It Work?
Schedule a Demo
Interested in how iDose can improve your patient outcomes?
Diane R. Mould, PhD
Dr. Diane R. Mould, Chief Scientific Officer (CSO) of Baysient, discusses individual variability in infliximab excretion and elimination. The variations seen in the individual pharmacokinetics of biologics highlight the need for more prospective data to further support effective personalized dosing. By focusing on important, modifiable factors for regulating drug levels, we can improve the efficacy of inflammatory disease treatments in clinical settings.
Latest Blog Post
Coronavirus (COVID-19) is officially a worldwide pandemic as it continues to spread globally. The doctors and researchers on the Baysient team are actively developing treatments for COVID-19 to help end the death toll it has caused around the world. For now, everyone’s focus should be…